Next Generation News and Research

RSS

Medivir reports net sales of SEK 444.6 m for 1 January - 30 June 2011

Medivir: Interim period (January 2011 - June 2011). Net sales were SEK 444.6 (35.7) m.

31 Aug 2011

Alcon chooses Bruker ContourGT-X8 Optical Surface Profiler

Bruker announced today that Alcon Corporation has selected the Bruker ContourGT-X8 Optical Surface Profiler to provide non-destructive, non-contact reference metrology for critical dimensioning and 3D characterization of Alcon's current and next-generation intra-ocular lenses.

From Bruker Nano Surfaces and Metrology 30 Aug 2011

Student researchers throughout Australia compete for annual award

Student researchers from throughout Australia will compete for state and national titles in the country’s leading competition for life science, biotechnology and bio-engineering students: the 2011 AusBiotech-GSK Student Excellence Awards. Applications are now open for the 2011 awards.

29 Aug 2011

BioAmber selects Sarnia as location for first North American biosuccinic acid plant

BioAmber Inc., through its subsidiary Bluewater Biochemicals has selected Sarnia, Ontario, Canada as the location for its first North American biosuccinic acid plant. The Sarnia plant will have an initial capacity of 17,000 MT and will be commissioned in 2013. Permitting work for the plant was initiated in June 2011. BioAmber currently produces and sells biobased succinic acid at a 3,000 MT capacity plant in France.

29 Aug 2011

ConversePoint plans to develop, commercialize next generation clinician communications

ConversePoint, a privately owned company based in Chicago, has announced its plans to develop and commercialize a communications platform for the healthcare industry that will significantly save clinicians time, hospitals millions in productivity costs and improve accountability measurements for critical events per the Joint Commission's National Patient Safety Goals along with the license of key Qualcomm technology.

29 Aug 2011

Redesigned vancomycin can kill deadliest antibiotic-resistant bacteria

A team of scientists from The Scripps Research Institute have successfully reengineered an important antibiotic to kill the deadliest antibiotic-resistant bacteria.

25 Aug 2011

Researchers trace source of latest cholera pandemic

Researchers have used next generation sequencing to trace the source and explain the spread of the latest (seventh) cholera pandemic. They have also highlighted the impact of the acquisition of resistance to antibiotics on shaping outbreaks and show resistance was first acquired around 1982.

25 Aug 2011

MSFHR announces recipients of 2010/11 health research scholar and trainee funding competitions

The Michael Smith Foundation for Health Research (MSFHR) is pleased to announce the recipients of its 2010/11 research scholar and trainee funding competitions. Of the more than 300 applicants, MSFHR has funded 95 individuals working in diverse fields of health research.

24 Aug 2011

NextDocs receives $10.3 million in Series A financing

NextDocs Corporation, the global leader in Microsoft SharePoint based software solutions for life sciences industries, today announced that the Company has received $10.3 million in a Series A financing from OpenView Venture Partners.

23 Aug 2011

GE launches new release of healthcare revenue cycle management solution

GE Healthcare, a leading provider of healthcare information technology, today launched Centricity Business 5.0, the next-generation revenue cycle management solution for hospital networks, academic medical centers, large practices and physician billing groups.

23 Aug 2011

IVAX Diagnostics net revenues decrease 0.4% to $4,375,000 for quarter ended June 30, 2011

IVAX Diagnostics, Inc., a fully integrated in vitro diagnostics company, reports its financial results for the quarter ended June 30, 2011.

23 Aug 2011

A CRADA for prostate disease research

Genomatix Software, the Uniformed Service University of the Health Sciences (USU), and the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) have entered into a Cooperative Research and Development Agreement (CRADA) to extend their collaborative endeavors in prostate disease research.

22 Aug 2011

Medicinal Genomics sequences entire genomes of two therapeutic Cannabis strains

Medicinal Genomics, a private company headquartered in Marblehead, Mass., USA and the Netherlands, announced today that it has sequenced the entire genomes of Cannabis sativa and Cannabis indica, representing two strains of the therapeutic plant.

19 Aug 2011

Maternal stress may disrupt masculinization of developing mouse brain

Sons of male mice exposed to prenatal stress are more sensitive to stress as adults, according to a study in the August 17 issue of The Journal of Neuroscience. These findings suggest experiences in the womb can lead to individual differences in stress response that may be passed across generations.

18 Aug 2011

PAREXEL recognized as Company of the Year for the Pharmaceutical Industry

PAREXEL International Corporation, a leading global biopharmaceutical services provider, has been named Company of the Year for the Pharmaceutical Industry in The Eighth Annual International Business Awards, the only global, all-encompassing business awards program honoring great performances in business.

From Parexel 17 Aug 2011

Young stressed females can impair future offspring, also improve resilience

The study found that stress experienced by young female rats can impair their future offspring, but can also improve resilience. The study also showed that providing the young stressed females with an enriched environment, can indeed ameliorate some of the effects.

17 Aug 2011

PERCH study to look at current and likely future causes of childhood pneumonia

Pneumonia kills more children around the world than any other disease, but the last major effort to study the causes of childhood pneumonia across many countries was conducted in the 1980's. This week, a groundbreaking new study called the Pneumonia Etiology Research for Child Health (PERCH) study gets off the ground.

17 Aug 2011

Curis initiates CUDC-101 Phase I combination trial in advanced head and neck cancer

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the first patient has been treated in a Phase I combination trial of CUDC-101.

17 Aug 2011

Kineta's next generation antiviral program receives $2.8 million NIH SBIR grant

Kineta, Inc. announced today its next generation antiviral program has received a 2.8 million dollar grant from the National Institute of Allergy and Infectious Disease, a part of the National Institutes of Health (NIH). Awarded under the Small Business Innovation Research (SBIR) program, the prestigious phase two grant will provide on-going support for Kineta's work on a new class of antiviral drugs targeting an array of global, deadly viruses.

12 Aug 2011

Advaxis completes ADXS-PSA prostate cancer construct pre-IND meeting with the FDA

Advaxis, Inc.,, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has completed a pre-IND (Investigational New Drug) meeting with the FDA on August 10 to discuss the development plan for ADXS-PSA, a construct for the treatment of prostate cancer.

12 Aug 2011